BioAge Labs (BIOA) Corporate presentation summary

Platform and strategy

• Focuses on developing therapies for metabolic diseases by harnessing human aging biology and large-scale molecular data sets, with over 150 million data points and 25,000+ profiles tracked for 50+ years.

• Validated discovery platform with ongoing pharma collaborations, including Novartis and Lilly, to identify novel drug targets related to exercise and healthy aging.

• Supported by a leadership team with extensive biopharma experience and a strong board, including former CEOs and managing partners from leading pharma and investment firms.

Lead program: BGE-102 (NLRP3 inhibitor)

• BGE-102 is an oral, brain-penetrant NLRP3 inhibitor with a unique, patented binding site and novel mechanism, showing best-in-class potency and safety in Phase 1 trials.

• Demonstrated >90% suppression of IL-1β and 86% reduction in hsCRP in obese subjects, with 93% achieving normalized hsCRP (<2 mg/L), aligning with injectable anti-inflammatories.

• Well-tolerated with only mild/moderate, self-limited adverse events and a wide safety margin.

• Strong intellectual property position with composition of matter protection through 2045.

Clinical development and results

• Phase 1 trials included healthy volunteers and obese participants, showing dose-proportional pharmacokinetics and sustained pharmacodynamic effects.

• In obese cohorts, BGE-102 led to 86% reduction in hsCRP, 44-62% reduction in IL-6, 30% reduction in fibrinogen, and 93% suppression of IL-1β at trough.

• Achieved therapeutic concentrations in CSF, supporting potential for CNS indications.

• Planned Phase 2a proof-of-concept in obesity and cardiovascular risk, with endpoints including hsCRP, metabolic parameters, and imaging.